Psoriatic arthritis

Obesity and Rheumatic Disease Presented as part of RheumNow's "The Obesity Imperative" campaign. https://t.co/d2fl4EJX8Q https://t.co/AZGfKRvZrx

Links:

Dr. John Cush @RheumNow( View Tweet )
Obesity and Rheumatic Disease Presented as part of RheumNow's "The Obesity Imperative" campaign. https://t.co/d2fl4EJX8Q https://t.co/DpihLZz5Ch

Links:

Dr. John Cush @RheumNow( View Tweet )
Obesity Journal Club: Tuesday Nite Rheumatology The Obesity Journal Club explores the TOGETHER PsA and STEP 9 trials and what emerging evidence tells us about the relationship between obesity, weight loss, and rheumatic disease. Panelists discussed the results of these trials, https://t.co/3C1RLyRj0b
Dr. John Cush @RheumNow( View Tweet )
Weight Loss Improves Psoriatic Disease Substantially! Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent https://t.co/BWeW7fzSC8
Dr. John Cush @RheumNow( View Tweet )
In 2022, Overweight & obesity affect 65.8% of Swiss PsA pts (vs gen pop.= 43%) and has increased since 2007. Obesity was assoc w/ elevated CRP (56% vs 37%), Inc Pt global assess (3.2 vs 2.8), & MD global (2.5 vs 2.1) & lower EQ-5D-3L(0.7 vs 0.8). https://t.co/xPoy4dgvlD https://t.co/aeB5N6LgCd

Links:

Dr. John Cush @RheumNow( View Tweet )
Obesity in Axial Spondyloarthritis: what are we missing beyond the scale? Obesity in axSpA is not a minor comorbidity. While obesity is more often discussed in psoriatic arthritis (PsA) due to the psoriasis-adipose tissue link which is mechanistically better studied and https://t.co/bFkoPmc0pC
Dr. John Cush @RheumNow( View Tweet )
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw https://t.co/evzPtaTWI4

Links:

Dr. John Cush @RheumNow( View Tweet )
Together PsA 52 wk data (n 271): ACR50 plus >10% wt loss - 39.2% w/ Taltz & Zepbound vs 1.7% w/ Taltz alone. Together PsO trial results (n 274): PASI100 plus >10% wt loss - 30.6% w/ Taltz & Zepbound vs 4.4% w/ Taltz alone. https://t.co/27TBZyL8l1 https://t.co/VdQJALdoJt

Links:

Dr. John Cush @RheumNow( View Tweet )
diet.better.jpg

Weight Loss Improves Psoriatic Disease Substantially!

Jack Cush, MD

Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent improvement in both psoriasis and psoriatic arthritis.

Read Article
RheumNow Podcast square

A Day of Infamy (9.11.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz

Read Article
Meta-analysis 24 studies (3015 hidradenitis suppurativa pts) taking IL-17 inhibitor, IBD adverse events were rare, w/ no difference in IBD risk betw IL-17i & PBO (0.23% vs 0 of 2572 vs 1066 pts respectively) thru wk 16. The reported assocn of IL-17 inhibitors w/ IBD risk is https://t.co/kDwR5Fc1zI
Dr. John Cush @RheumNow( View Tweet )
Difficult PsA is called ‘difficult-to-manage’ (D2M) or ‘treatment-refractory’ dz (TRD). Data from 5 Nordic PsA registries 14,362 ps, D/Cs of ≥2/≥3/≥4 b/tsDMARDs in 36%/18%/10%. Freq of D2M low 2%/3%/3%, & TRD was 1.2%/1.2%/0.8%. Female #s, depression, & opioids incr w/ # of https://t.co/FkQU5BVRn2
Dr. John Cush @RheumNow( View Tweet )
High BMI decreases the odds for MDA in PsA, esp w/ TNFi Rx (but not Inflx, IL-17i, IL-12/23i, IL-23i, JAKi). Longitudinal PsA cohort 1291 pts (mean BMI 29); Higher BMI independently assoc w/ signif. lower odds for MDA (OR 0.97), also female, age, smoking, FM & Xray damage. https://t.co/zAJ8Pmk1HY
Dr. John Cush @RheumNow( View Tweet )
Join us for the first of four webinars this month! This Journal Club will explore the TOGETHER PsA and STEP 9 trials, and what emerging evidence tells us about the complex relationship between obesity, weight loss and rheumatic disease. The authors and leading experts will: • https://t.co/xpnqim1VKH
Dr. John Cush @RheumNow( View Tweet )
Join us for the first of four webinars this month! Our Journal Club explores the TOGETHER PsA and STEP 9 trials, and what emerging evidence reveals about obesity, weight loss and rheumatic disease. Featuring Drs. Philip Mease, Tom Appleton and Jack Cush. https://t.co/KkVJPyhKF1
Dr. John Cush @RheumNow( View Tweet )
NEJM images: Jaccoud’s arthropathy is a chronic, deforming;from laxity of the ligaments & tendons (not damage to bone & cartilage). Deformities are reducible & no erosions on Xray. Jaccoud’s mimics RA, but most seen w/ SLE. https://t.co/99WDNcpT5c https://t.co/EdiGW1dDWY

Links:

Dr. John Cush @RheumNow( View Tweet )
NEW FROM EULAR: A real-world analysis of predictors of IBD in PsA. 🔎 In patients with PsA, signs and symptoms of IBD may appear before diagnosis, but do we know what to look for? Explore the poster: https://t.co/JX0Y0AQ07N Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/zx9kjsiZfZ

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Treating Obesity is Disease-Modifying (9.4.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  New drugs approved, new drugs halted and some drugs out of control. Ready to test your knowlege? Take this week's quiz!

Read Article
empty bed

Sleep and Obesity: A Bidirectional Relationship

Jack Cush, MD

In July 2026, JAMA concisely reviewed the bidirectional relationship between sleep health and obesity. Obesity affects roughly 40% of US adults and sleep problems affect nearly one-third. This review outlines the biological mechanisms and clinical interventions relevant to weight management.

Read Article
DERM on RheumNow PODCAST (August 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. Dermatology drugs, biologics, and JAK inhibitors - their use, https://t.co/u2sJqCgDJS
Dr. John Cush @RheumNow( View Tweet )
Rheums! Do you have a Rheumatology question or case for Dr. Cush? Record it here, and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/LZ59KW8HdA https://t.co/DwHdvpTYax

Links:

Dr. John Cush @RheumNow( View Tweet )
SELECT-PsA 2 subanalysis of 195 active PsA not responding to TNFi shows switching to upadacitinib 15 (vs PB) was superior @wk 24 - ACR20 (58% vs 22%), ACR50 (38% vs 9.5%), ACR70 (22% vs 0%), MDA (24% vs 3%) & maintained thru wk 152. Switching MOAs makes sense! https://t.co/YEkZuQ95Mu
Dr. John Cush @RheumNow( View Tweet )
Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/lKBhEnTcKB
Dr. John Cush @RheumNow( View Tweet )
20 long-standing PsO pts (freq nai,scalp dz) (b/tsDMARD-naive) Rx w/ OL apremilast 30 bid x 6 mos. Enthesitis (MRI or HR-pQCT) stable, PsAMRIS stable; no new erosions, but PASI (11-->5) & TJC signif improved (3.2-->0.8) https://t.co/UjACvXyvKs https://t.co/xfQGcW0yz7

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Rheum Scholarship (8.21.2026)

Jack Cush, MD

Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.

Read Article

Therapeutic Updates

Label update: Structural damage progression in active PsA

Sponsored by Johnson & Johnson Medical Affairs
J&J RX Update
Listen to Dr. Catherine Bakewell’s review of clinical data from a recent label update.
Read Post

PsA GRAPPA domains: Outcomes With a JAKi

AbbVie April 2026 RX Update Sponsored Image
Dr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains.
Read Post

Recent Blogs

Advanced Practice Rheum

Methotrexate

Jack Cush, MD
APR MTX Cover
In this session, Dr. Jack Cush reviews methotrexate.
Read Article
Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article

Best of 2022: The Enthesitis Challenge in Psoriatic Arthritis

Robert Chao, MD
heel enthesitis spur calcaneal
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do! 
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • PsA Topic Podcast compilation
  • EULAR 2026 Daily Podcast Day 4c
  • EULAR 2026 Daily Podcast Day 4a
×